SYK · 10-Q · 2026Q3 · Full report

Guidance / Outlook

STRYKER CORP · 2026-10-30 · Importance 33 · Surprise 24

Management expects segment mix to have an unfavorable impact on gross margin for the foreseeable future. This outlook reflects anticipated faster sales growth in the lower-gross-margin MedSurg and Neurotechnology segment than in Orthopaedics. The filing does not quantify the expected margin impact or provide a specific end date.

Key facts

• Stryker expects segment mix to have an unfavorable gross-margin impact for the foreseeable future because it anticipates faster sales growth in lower-gross-margin MedSurg and Neurotechnology than in Orthopaedics. source
• Stryker's Peripheral Vascular goodwill valuation assumptions considered supply constraints and the competitive environment; future impairment charges could be required if projected cash flow, revenue, or profitability is not achieved or the weighted-average cost of capital rises. source
• Stryker's future results may be adversely affected by uncertainty about the impact of the cybersecurity incident first reported on March 11, 2026, on operations and financial results. source
• Stryker anticipates supporting short-term liquidity and operating needs with cash from operations, commercial paper, and existing credit lines. source
• Stryker may continue to access capital and credit markets from time to time and believes its strong investment-grade short- and long-term debt ratings should enable debt refinancing as needed. source
• Stryker is involved in ongoing proceedings, legal actions, and claims arising in the normal course of business, including product, labor, tax, and intellectual-property matters. source